Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a report issued on Friday.

Several other research analysts have also issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. Citigroup dropped their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Sanford C. Bernstein lowered their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. Finally, Piper Sandler cut their price objective on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.70.

Arrowhead Pharmaceuticals Trading Down 4.2 %

Shares of Arrowhead Pharmaceuticals stock opened at $19.50 on Friday. Arrowhead Pharmaceuticals has a 52-week low of $17.05 and a 52-week high of $39.83. The firm has a market capitalization of $2.43 billion, a PE ratio of -3.88 and a beta of 0.91. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The company’s fifty day moving average price is $21.23 and its two-hundred day moving average price is $23.09.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,748 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the transaction, the director now directly owns 44,125 shares in the company, valued at approximately $966,337.50. This represents a 7.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.50% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. lifted its stake in Arrowhead Pharmaceuticals by 9.4% in the third quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company’s stock valued at $373,000 after buying an additional 1,658 shares during the period. World Investment Advisors LLC increased its stake in shares of Arrowhead Pharmaceuticals by 3.8% in the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after acquiring an additional 700 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Arrowhead Pharmaceuticals by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock valued at $57,426,000 after acquiring an additional 26,171 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $345,000. Finally, Wellington Management Group LLP grew its holdings in Arrowhead Pharmaceuticals by 1.5% during the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock valued at $1,199,000 after purchasing an additional 886 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.